Zymeworks Stock Forecast, Price & News

-0.45 (-1.18 %)
(As of 06/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume471,905 shs
Average Volume494,110 shs
Market Capitalization$1.74 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

Zymeworks logo

About Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.57 out of 5 stars

Medical Sector

496th out of 2,102 stocks

Pharmaceutical Preparations Industry

241st out of 832 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Zymeworks (NYSE:ZYME) Frequently Asked Questions

Is Zymeworks a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 3 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zymeworks stock.
View analyst ratings for Zymeworks
or view top-rated stocks.

What stocks does MarketBeat like better than Zymeworks?

Wall Street analysts have given Zymeworks a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zymeworks wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Zymeworks

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) posted its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($1.04) by $0.17. Zymeworks had a negative trailing twelve-month return on equity of 45.36% and a negative net margin of 619.31%.
View Zymeworks' earnings history

How has Zymeworks' stock been impacted by Coronavirus (COVID-19)?

Zymeworks' stock was trading at $32.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ZYME stock has increased by 17.1% and is now trading at $37.78.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ZYME?

9 brokers have issued 1 year price objectives for Zymeworks' shares. Their forecasts range from $38.00 to $74.00. On average, they anticipate Zymeworks' stock price to reach $51.33 in the next year. This suggests a possible upside of 35.9% from the stock's current price.
View analysts' price targets for Zymeworks
or view top-rated stocks among Wall Street analysts.

Who are Zymeworks' key executives?

Zymeworks' management team includes the following people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 49, Pay $877.66k)
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Exec. VP of Bus. Operations & CFO (Age 49, Pay $589.86k)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 58, Pay $606.71k)
  • Ms. Kathryn O'Driscoll, Chief People Officer (Age 57, Pay $497.22k)
  • Dr. Diana F. Hausman, Exec. Advisor (Age 58, Pay $636.61k)
  • Dr. Neil Josephson M.D., Interim Chief Medical Officer
  • Mr. James Daniel Guylain Priour, Chief Commercial Officer (Age 54)
  • Dr. David Poon Ph.D., VP of Bus. Devel. and Alliance Management
  • Dr. Jennifer Kaufman-Shaw L.L.B., Ph.D., LLB, VP of Intellectual Property (Age 71)
  • Ms. Wajida Leclerc, VP of HR (Age 61)

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks CEO Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among Zymeworks' employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.38%), Credit Suisse AG (4.96%), Cormorant Asset Management LP (4.33%), Morgan Stanley (3.77%), Armistice Capital LLC (3.57%) and Price T Rowe Associates Inc. MD (2.57%). Company insiders that own Zymeworks stock include Ali Tehrani, Diana Hausman, James Priour, Kathryn O'driscoll, Neil A Klompas and Troy Cox.
View institutional ownership trends for Zymeworks

Which institutional investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, Redmile Group LLC, First Light Asset Management LLC, Goldman Sachs Group Inc., D. E. Shaw & Co. Inc., Royal Bank of Canada, and Northern Trust Corp. Company insiders that have sold Zymeworks company stock in the last year include Ali Tehrani, Diana Hausman, James Priour, Kathryn O'driscoll, and Neil A Klompas.
View insider buying and selling activity for Zymeworks
or view top insider-selling stocks.

Which institutional investors are buying Zymeworks stock?

ZYME stock was purchased by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Cormorant Asset Management LP, Credit Suisse AG, UBS Asset Management Americas Inc., Scion Asset Management LLC, JPMorgan Chase & Co., Morgan Stanley, and SG Americas Securities LLC. Company insiders that have bought Zymeworks stock in the last two years include Ali Tehrani, and Troy Cox.
View insider buying and selling activity for Zymeworks
or or view top insider-buying stocks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $37.78.

How much money does Zymeworks make?

Zymeworks has a market capitalization of $1.74 billion and generates $38.95 million in revenue each year. The company earns $-180,550,000.00 in net income (profit) each year or ($3.58) on an earnings per share basis.

How many employees does Zymeworks have?

Zymeworks employs 352 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

Where are Zymeworks' headquarters?

Zymeworks is headquartered at 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]

This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.